Aktis Oncology

Public

Boston, MassachusettsBiotechhttps://www.aktisoncology.com/

Aktis Oncology is now publicly traded

The data on this page reflects Aktis Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jan 8, 2026

Last Round

Series B

Sep 30, 2024

Total Funding Raised

$696.4M

Company Overview

Aktis Oncology is a biotechnology company that develops targeted radiopharmaceuticals for the treatment of various solid tumor cancers.

Sector

Biotech

Verticals

Life Sciences, Oncology

AI Layer

Application

Keywords

targeted radiopharmaceuticalsradiopharmaprecision oncologysolid tumor treatmentminiprotein radioconjugatescancer therapeuticsbiotech drug discoverytargeted radiation therapydrug development platformbiopharma partnershipclinical stage biotechtheranostics

Aktis Oncology Comparables

Compare Aktis Oncology with similar companies based on industry and business-model similarity.

Aktis Oncology comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Ratio Therapeutics Inc.	89%
Alpha-9 Oncology	86%
ARTBIO	86%

View all Comparables

Aktis Oncology Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO	Jan 8, 2026
Series B	Sep 30, 2024
Series A Extension	Aug 25, 2022
Series A	Mar 18, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Matthew Roden

President And Chief Executive Officer, And Member Of The Board Of Directors

Executive Team

Kyle Kuvalanka

Chief Financial, Chief Financial Officer

Executive Team

Shulamit Ron-Bigger

Chief Operating Officer

Executive Team

Aktis Oncology Investors

Notable investors and investment history

Aktis Oncology investors
Investor	Rounds
EcoR1 Capital	Series B, Series A, Series A Extension
Janus Henderson Group	Series B
MPM Capital	Series B, Series A Extension, Series A
RA Capital Management	Series B
TCG Crossover	Series A, Series B, Series A Extension
A. M. Pappas & Associates	Series A Extension
Mirae Asset	Series A Extension

View all Investors

Aktis Oncology Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Aktis Oncology Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersBoston, Massachusetts

Employee Range88

Year Founded2020

Last FundingSep 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?